Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bay-678 SCHEMBL1245297 | 1.00 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-677 SCHEMBL4179543 | 1.00 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1245423 | 0.93 | ELANE (0.87) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1245171 | 0.92 | ELANE (0.85) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL10013429 | 0.91 | ELANE (0.82) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL7905406 | 0.91 | ELANE (0.82) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL2896989 | 0.89 | ELANE (0.80) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1243900 | 0.88 | ELANE (0.79) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL14899948 | 0.87 | ELANE (0.77) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL395186 | 0.86 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | claimed |
| US-20240382472-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | MEREO BIOPHARMA 4 LIMITED (GB) | 2024-11-21 | — | — | US | disclosed |
| EP-4419102-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | Mereo Biopharma 4 Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118265527-A | Neutrophil elastase inhibitors for the treatment of fibrosis | 美莱奥生物制药第四有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-3575791-B1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY INC (JP) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023067103-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | MEREO BIOPHARMA 4 LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| CN-110547288-B | Blood processing method and blood collection tube | 爱科来株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-110547288-A | Blood processing method and blood collection tube | ARKRAY INC | 2019-12-10 | — | — | CN | disclosed |
| EP-3575791-A1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY, Inc. (JP) | 2019-12-04 | — | — | EP | disclosed |
| EP-1730121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER IP GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20080021053-A1 | Heterocyclic Derivatives | BAYER HEALTHCARE AG (DE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021053-A1 | Heterocyclic Derivatives | BAYER HEALTHCARE AG (DE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021053-A1 | Heterocyclic Derivatives | BAYER HEALTHCARE AG (DE) | 2008-01-24 | — | — | US | disclosed |
| EP-1730121-A2 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer HealthCare AG (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2005082863-A2 | 1,4 DIARYL-DIHYDROPYRIMIDIN-2 ONES AND THEIR USE AS A HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082863-A2 | 1,4 DIARYL-DIHYDROPYRIMIDIN-2 ONES AND THEIR USE AS A HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2004024700-A1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | BAYER HEALTHCARE AG (DE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021053-A1 | Heterocyclic Derivatives | TNNI3, CYP11B2, TNNT2 | ELANE 132/4885CYP2C9 838/4885ADRB1 72/4885 |
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | PTGIS, PTGIR, FPR1 | ELANE 59/4885CYP2C9 4171/4885ADRB1 158/4885 |
| US-20240382472-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | SERPINB1, ELANE, MMP8 | ELANE 2/4885CYP2C9 2725/4885ADRB1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.